22 results about "Complement Factor D" patented technology

Disclosed are compounds, pharmaceutical compositions and uses thereof as complement factor D inhibitors, specifically a compound represented by formula (I), its tautomers, its stereoisomers, its prodrugs, or any one of the foregoing pharmaceutically acceptable salts, or any one of the foregoing solvates, wherein the compound has excellent inhibitory activity against complement factor D and has excellent pharmacokinetic and pharmacodynamic activity. JPEG2024533782000131.jpg47170

Disclosed in the present invention are a preparation method for a complement factor D inhibitor, an intermediate thereof, and a preparation method for an intermediate. The present invention provides a preparation method for a new complement factor D inhibitor, a new intermediate, and a preparation method for an intermediate. The selectivity of a reaction is improved by means of the new intermediate, the material conversion rate of each step of a route is high, a reaction type is common, the length of the route is moderate, and the obtained products can all be purified by means of a conventional method to obtain a target product, thereby reducing the production costs, and facilitating industrial production.

The present invention provides antagonizing antibodies that bind to complement factor D (CFD), conjugates thereof, and methods of using same. The anti-CFD antibodies can be used therapeutically alone or in combination with other therapeutics to treat age related macular degeneration and other diseases.

To provide further complement inhibitors with therapeutic potential in the treatment of many disorders.SOLUTION: Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.SELECTED DRAWING: None

The present invention relates to the prediction and early diagnosis of acute kidney injury (AKI). The methods provide biomarkers that correlate with a patient's risk of developing AKI, or the presence of early AKI. The invention also provides devices and kits for predicting the risk of development of AKI and for diagnosing AKI.SOLUTION: A method for predicting the risk of occurrence of acute kidney injury (AKI) or for early diagnosis of AKI in a subject, the method comprising: a. determining in a sample obtained from the subject the amount of at least one biomarker selected from the group consisting of complement factor D and insulin-like growth factor binding protein 1 and combinations, isoforms, fragments and variants thereof.SELECTED DRAWING: None

Disclosed herein are monoclonal antibodies that specifically bind to human mature Factor D and that do not bind to human Pro-Factor D, monoclonal antibodies that specifically bind to human Pro-Factor D and do not bind to human mature Factor D, and monoclonal antibodies that bind to both human mature Factor D and human Pro-Factor D. Also disclosed are methods of using the monoclonal antibodies, and compositions comprising the same, for detection of the mature and / or the pro-form of Factor D in biological samples, to determine the status of the Alternative Pathway of Complement (APC) in a mammalian subject, or to determine the status of Factor D after treatment with a MASP-3 inhibitory agent which inhibits the conversion of Pro-Factor D to mature Factor D.

The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof.

Provided herein are dual-antigen binding molecules, and nucleic acid sequences encoding such molecules, that bind human complement factor D (FD) and human complement component 2 (C2). In particular embodiments, the FD binding region of the dual-antigen binding molecules comprises light and heavy chain variable regions, and the C2 binding region comprises a first single monomeric variable antibody domain (aka VHH), and optionally second single monomeric variable antibody domain. In certain embodiments, the dual-antigen binding molecules are used to treat complement-related diseases (e.g., dysregulated complement activation diseases).

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

The present invention discloses a compound as a complement factor D inhibitor, a pharmaceutical composition and application thereof, and specifically discloses a compound represented by formula (I), its tautomers, its stereoisomers, its prodrugs, or a pharmaceutically acceptable salt of any of the foregoing, or a solvate of any of the foregoing. The compound has good inhibitory activity against complement factor D and has excellent pharmacokinetic and pharmacodynamic activity.

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

The present invention provides multispecific (e.g., bispecific) constructs that target complement factor D and another complement protein (e.g., C2, C5), nucleic acids encoding such multispecific constructs, and their use for the treatment of complement mediated diseases. Also provided are novel antibody constructs that specifically recognize C5, nucleic acids encoding the antibody constructs, and uses thereof.

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof.

Provided is an isolated antigen binding protein which can bind to complement factor D，a preparation method and an application thereof.

The present disclosure relates generally to methods of treating a subject having or at risk of developing macular degeneration by administering a complement factor D (CFD) inhibitor to the subject and to identifying subjects at increased risk of developing macular degeneration.

The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof. The methods involve subjecting an intermediate in the synthesis of a complement factor D inhibitor to a t-butyl ester deprotection reaction using a weak base.

Disclosed in the present invention are a compound as a complement factor D inhibitor, a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a compound as represented by formula (I), a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a solvate of any of the foregoing. The compound has a good inhibitory activity on complement factor D, and exhibits good pharmacokinetic and pharmacodynamic activities.

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.